Zebeth Media Solutions

Startups

Let’s check in on community-focused startups • ZebethMedia

Over the past few years, community has been a buzzword for tech startups looking to sell a product or service based on their definition of a useful network. The pandemic stress-tested these business models, with some companies seeing that consumers weren’t willing to pay fees in exchange for advice they could find on Twitter, while others realized that focusing on a target user was more important than finding the biggest total addressable market possible. It’s part of the reason I had so much fun interviewing founders from Clubhouse and Chief last week at ZebethMedia Disrupt. I spoke to the founders of these companies to understand how they’ve evolved to deal with a bewildering new normal, and while a social audio app and a private membership community for women in leadership are quite different in strategy, they shared the same vibe: Less is more. Clubhouse’s product-market fit Paul Davison, Clubhouse co-founder and CEO, was fast to address what others described as Clubhouse’s fall from grace. He said that the app’s early hype saw it grow 10x in users month over month, a boom that broke a lot of the underlying infrastructure of the app. For months, he said, people had a bad experience on the app because of tech issues and the inability to find a room that matched their interests.

With Musk’s purchase completed, NYSE will delist Twitter stock on Election Day • ZebethMedia

To get a roundup of ZebethMedia’s biggest and most important stories delivered to your inbox every day at 3 p.m. PDT, subscribe here. Happy Friday! Haje is enjoying some down time on the East Coast, so I am running solo. As you can see from the not-so-surprising move by Elon Musk last night and the sheer number of Twitter stories from our fabulous consumer tech team today, it has been all Twitter, all day. We promise to give you a little bit of that, of course, and a little of what else we’ve been working on. Let’s dive in, shall we?  — Christine The ZebethMedia Top 3 Flying the public coop: Now that Elon Musk owns Twitter, its days are numbered as a public company. In fact, Ivan writes, Twitter will be delisted on November 8 — voting day for the U.S. midterm elections. Caging the bird: Over to Europe, where just a few hours into actually owning Twitter, Musk already found himself on the wrong end of European Union officials, who corrected him after he tweeted about how free he thinks Twitter is now. Natasha L has more. Big Tweet Chief: Reports now say that Musk will take the CEO role for himself, Ivan writes, after he ousted Twitter’s four top executives, as reported by Amanda.  For more news on the blue bird, head down to the Big Tech Inc. section, where we have you covered. Startups and VC Unfortunately, the hits keep coming for 54gene, an African genomics startup focused on providing more African genetic material to pharmaceutical research — there is just 3% now, Tage reports. After some months of layoffs and a CEO exit, the company confirmed that it not only made yet another round of layoffs — this time of 100 people — but it also slashed its valuation by over $100 million. And we have three more for you: Robot riot: Galen Robotics has a new robot that will assist with ear, nose and throat surgeries. Oh, and it secured $15 million in new funding, Andrew reports. Follow the yellow brick road: Game studio Hidden Door is using narrative AI to turn fiction into immersive role-playing experiences, and Rebecca writes it is testing out “The Wizard of Oz.” Does anyone else use this word?: I was delighted to see that there is a company named Skidattl. The company is using augmented reality to show users what people are doing around them, in what Rebecca writes is “like a Bat-Signal for fun.” 5 ways biotech startups can mitigate risk to grow sustainably in the long run   Image Credits: jayk7 (opens in a new window) / Getty Images Thanks to R&D and clinical trials, life science startups have long lead times before they can bring their capital-intensive products to market. “But,” asks Omar Khalil, a partner at Santé Ventures, “what happens when the funding suddenly dries up?” In a guest post for TC+, he shares five strategies for biotech startups that are trying to stay warm through the winter ahead. “It’s still too early to know whether this is a short-term correction, or if it’s a new normal that will be maintained for the foreseeable future.” Three more from the TC+ team: ZebethMedia+ is our membership program that helps founders and startup teams get ahead of the pack. You can sign up here. Use code “DC” for a 15% discount on an annual subscription! Big Tech Inc. As promised, we have even more Twitter news for you to enjoy. As I write this, several of my colleagues hopped on Twitter Spaces to talk about all this. One of the latest bits of news from Taylor was that Elon Musk was forming a content moderation “council” to make certain decisions — for example, about account reinstatements for, cough, Donald Trump. Here’s two more: Catching you up on more earnings reports: And we have four more for you:

Cruz Foam’s chitin-based packaging brings in $18M as industries scramble to go green • ZebethMedia

The best way to remove plastics from the ecosystem is to make sure they never get there in the first place, and Cruz Foam is well on its way to replacing some of the worst ones out there with its naturally-derived and compostable alternative — and the company just landed an $18M series A to do it faster. Cruz Foam creates materials out of chitin, which is what makes up the shells of most crustaceans, like crabs, shrimp, lobsters and many land insects as well. It’s strong, stable, totally biodegradable, and boy is it plentiful: there are mountains of this stuff for the taking outside every seafood processing plant. The company, whose founder John Felts I met in Alaska during the Accelerator at Sea, has been scrappily humming along prototyping various ways to turn chitin and a few other natural ingredients into a material that can replace polystyrene foam (EPS, like Styrofoam) and other common plastic packaging. They got their first big break last year when Whirlpool tapped them to make a few pieces for their appliance boxes, and now, having proved out the idea, Cruz Foam is getting ready to break into half a dozen more industries. “A lot of what we’re focusing on is those two initial areas – packaging that replaces polyethylene and polystyrene foam. But demand is growing in other avenues: cold chain, CPG [consumer packaged goods], ecommerce, etc. People asking about construction, or how we can do injection molding. It’s exciting to see so much potential,” said Felts. The need to prototype and test these possibilities is one reason for the company raising such a considerably-sized round. They just bought a new extruder (foam like this is essentially printed using specialized equipment) and have been experimenting with all kinds of new form factors, driven by partners and potential partners across many industries. It helps that a number of laws and trends have steadily pushed companies towards eco-friendly alternatives to plastic or even cardboard. “Putting the ownership of waste and the collection back on the people that produce packages, you’re seeing a broad change in ESG goals,” he said. “It used to be, ‘OK, we’re going to be carbon neutral by 2030.’ Like, what does that mean? So we’re seeing real granularity in what that means now — is it packaging, is it energy use, what are the milestones, the two-year, three-year marks? That’s how you know they’re serious.” Cruz Foam enclosures for a piece of consumer electronics. Suddenly, it seems, everyone from goods manufacturers to the people who produce plastic foam are looking for full-stack alternatives, even if there isn’t cost parity. They see the writing on the wall, and the idea of being caught unprepared when a (say) ban on EPS kicks them out of west coast markets is a scary one. Felts said that the company is in talks with several of the largest manufacturers of packaging foam, working with them on a deal that would see them actually making chitin-based materials and sharing the glory with Cruz Foam. The truth there, though, is that neither party has much choice. The manufacturers need to prepare for a greener future, and Cruz Foam doesn’t have even a fraction of the machines it would need to meet demand. Felts said they never intended to actually do the manufacturing. “You literally can’t. Buying this extruder, it took 6 months,” he said, and even that was a miracle. “Can you imagine scaling a business if it took you two years to get one machine? You have to use the infrastructure that’s in place.” A ribbon of foam is extruded. Whoever makes it, you’ll probably be seeing more of their products soon. The company showed me some prototypes and new verticals it was working on, though it can’t announce any of its new partners or customers until the contracts or agreements are finalized, or in some cases until the requisite patents are filed. Suffice it so say that the company is going well beyond simply replacing a foam insert here and a molded shape there. The products Cruz Foam makes are generally compostable in the most broadly accepted sense, that you could just throw them in your yard and they’ll be gone in a month or two (and might even give your plants a boost). But because it’s being mated with cardboard and other materials, the company continues to face the challenge of how to make these things mesh with existing municipal waste systems. Is it recyclable according to Sacramento’s definition of the word? What about yard waste — does it technically break the rule there, and does anyone care? “The government needs to define standards for a new gen of compostable products – you’ve got to make it a no-brainer for customers,” Felts said. At least even if it goes in the wrong bin, it still degrades gracefully. The $18 million funding round was led by “global problem-solving organization” Helena, with participation from One Small Planet, Regeneration.VC, At One Ventures, and SoundWaves. The money will go towards expanding operations as well as R&D. “Out biggest focus is commercial production and revenue generation, until next year,” he said. “We’re filing tons of patents. A lot of growing the operational footprint of this company; we’re moving to new HQ, now up to 30 people.” With Cruz Foam focusing on the creative and sales work and working with existing manufacturers to actually make the stuff, 2023 could be the year the company goes from niche to mainstream. Watch your doorstep for the trademark CF (or as I prefer to see it, interlocking crustacean claws) on or in your delivery.

Fundraising beyond the Bay Area, web3 gaming, TDD prep checklist • ZebethMedia

In a previous era, aspiring journalists relocated to New York, would-be actors made pilgrimages to Hollywood, and plucky tech founders moved to the Bay Area so they could attract capital and talent. But San Francisco is no longer the center of the startup universe, and it hasn’t been for a while. Cities like Boulder, Detroit and Austin had emerging tech ecosystems long before the pandemic forced VCs to start taking pitches via Zoom, and social media has leveled the playing field when it comes to networking and PR. Full ZebethMedia+ articles are only available to membersUse discount code TCPLUSROUNDUP to save 20% off a one- or two-year subscription “We noticed a couple of years ago, in looking at our own analytics, that most of our deals were coming through Twitter,” said Elizabeth Yin, co-founder and general partner of Hustle Fund, last week at ZebethMedia Disrupt. “If I look at my portfolio, my companies that are active on Twitter actually do have an easier time raising money because investors feel like they know them.” Reporter Dominic-Madori Davis moderated a discussion with Yin, Mike Asem (founding partner of M25), and Accel partner Rich Wong that elicited suggestions for early-stage founders who don’t live in the 415 area code and spilled the tea about “the emerging markets on their radars.” If you’re interested in the entire conversation, there’s a link to a video at the end of the article. Keep an eye out for more recaps from TC Disrupt in the coming days. Thanks for reading, Walter ThompsonEditorial Manager, ZebethMedia+@yourprotagonist 5 tips for launching in a crowded web3 gaming market Image Credits: Chelsea Sampson (opens in a new window) / Getty Images Every online product requires some network effect, but gaming is unique: Without large, loyal and enthusiastic customers, there’s no way to build products that can be monetized. Play-to-earn games (P2E) are particularly susceptible to this problem, which is why “building a game that succeeds in the long term means developing monetization strategies that can weather market ebbs and flows,” says Corey Wilton, co-founder and CEO of Mirai Labs, the gaming studio behind Pegaxy. In this primer for P2E founders, Wilton shares suggestions for how to approach investors, explains why tokens are not a reliable fundraising vehicle and discusses the recent “shift toward Web 2.0 monetization.” A prep checklist for startups about to undergo technical due diligence Image Credits: Pixelimage (opens in a new window) / Getty Images On Tuesday, founder and CEO of codebase analytics company Sema, Matt Van Itallie, shared a guest post for founding teams who are about to begin technical due diligence before an investment or acquisition. On Wednesday, he followed up with a detailed checklist for C-level executives and senior managers responsible for helping VCs determine whether their “codebase is safe enough for investment.” Product roadmap Code quality Code, network and information security Intellectual property Development process Engineering team contributions DevOps Pitch Deck Teardown: The Palau Project’s $125k pre-seed deck Image Credits: Palau Project (opens in a new window) Fundraising takes many forms, but because pre-seed founders are so often coaxing money from family and friends to validate their ideas, it can raise the emotional stakes. To raise money for The Palau Project, an app that lets users find the environmental impact and nutritional benefits of packaged food, founder Jerome Cloetens put together a 22-slide deck with a $500,000 goal. In the end, the team raised just $125,000. Dear Sophie: How can early-stage startups improve their chances of getting H-1Bs? Image Credits: Bryce Durbin/ZebethMedia Dear Sophie, We have a stealth early-stage biotech startup. Do we qualify to petition a co-founder on STEM OPT for an H-1B in the lottery? Is it worth it or are there better alternatives? — Budding Biotech 3 VCs explain how founders can stand out when pitching Image Credits: Kelly Sullivan (opens in a new window) / Getty Images There’s a lot of wisdom in corny motivational writing. For instance, this quote by Will Durant, a historian and philosopher: We are what we repeatedly do. Excellence, then, is not an act, but a habit. A great pitch requires more than charm and storytelling skills: investors expect founders to understand their market and competitors, and help them prepare before the meeting begins. “I generally recommend having almost like a teaser version of the deck with enough data and information to give us a sense of where you are in terms of the journey of your company,” said Jomayra Herrera, a partner at Reach Capital. “Just enough information so that we come prepared to the meeting.” 5 ways biotech startups can mitigate risk to grow sustainably in the long run Image Credits: jayk7 (opens in a new window) / Getty Images Thanks to R&D and clinical trials, life science startups have long lead times before they can bring their capital-intensive products to market. “But,” asks Omar Khalil, a partner at Santé Ventures, “what happens when the funding suddenly dries up?” In a guest post for TC+, he shares five strategies for biotech startups that are trying to stay warm through the winter ahead. “It’s still too early to know whether this is a short-term correction, or if it’s a new normal that will be maintained for the foreseeable future.”

Latinx founders see VC funding drop as investors retreat from underrepresented cohorts • ZebethMedia

The latest Crunchbase data shows that Latinx-founded companies in the United States raised $250 million out of the $39.85 billion allocated in venture funds in the U.S. this Q3 — or about 0.63%.1 The Q3 sum is a sharp decrease from the $2.3 billion the cohort raised in Q3 last year and a dramatic decline from the $1.3 billion raise in Q2 this year. In total, 1.5% of all venture dollars so far in 2022 have been allocated to Latinx-founded companies, a drop from 2.5% last year, according to the Crunchbase analysis. The numbers are not surprising. Minorities and women overall are seeing dramatic dips in venture funding this year. ZebethMedia previously reported that Black founders raised $187 million this Q3, which meant, given historical data trends, the amount allocated to Latinx-founded companies wouldn’t be too far from that sum. Meanwhile, PitchBook found that female-founded companies have raised 1.9% of all venture funds so far this year, which is, again, a drop from the 2.4% the group raised last year. ZebethMedia noted before that investors tend to pull back toward their old networks to fund the founders who are familiar to them amid economic downturns — and those people tend to be white men. The somewhat encouraging news is that funding for early-stage Latinx-founded companies is on pace to exceed 2021’s total; much of the decline that we see in the above numbers came from a decrease in late-stage financing. The reality remains that women and minorities are not faring well right now when it comes to raising VC, and promises of change have dissipated. Last year, Latinx-founded U.S. companies raised $8.5 billion. Through the end of Q3 2022, that number stands at $2.7 billion, meaning it won’t even come close to passing last year’s record-breaking sum.

5 ways biotech startups can mitigate risk to grow sustainably in the long run • ZebethMedia

Omar Khalil is a partner at Santé Ventures, where he focuses primarily on biotechnology and medical technology companies. The unprecedented explosion of investment in life sciences over the past decade has resulted in incredible new therapies for patients, strong financial returns for companies and an overall increase in translational research, which is critical to advancing the next generation of therapies. It has also led to eye-popping levels of capital raised by early-stage companies, some of which were years away from entering the clinic with their first product. Naturally, a generous flow of financing generates excitement for everyone involved. Capital is the fuel that advances scientific and technological innovation, and it means a life science startup can create products that benefit the world at large. But what happens when the funding suddenly dries up? In the world of biotech, for example, it’s extremely capital intensive to develop multiple products that are all going through clinical trials simultaneously. The infrastructure needed to maintain these different programs can be too unwieldy to weather a financial drought. A better approach would be to focus on a lead program — a single product that they can take through various stages of development, ultimately leading to FDA approval. In fact, lead programs validate the value of an underlying platform, enabling companies to raise capital through licensing and partnerships. Founders shouldn’t let peer pressure or investor check size mandates dictate their financing strategy. There will always be ebbs and flows in funding, so here are five ways life science startups can optimize for success regardless of the economic climate. Don’t confuse successful fundraising with a successful company At the end of the day, fundraising is a means to an end. The mission for most life science startups is to improve patient outcomes. However, science is hard, and cash in the bank does not overcome the complexities of human biology. Plenty of companies have successfully raised significant amounts of capital but were never successful in developing a beneficial product, therapy or technology. While not a perfect proxy, the value at which a venture-backed company exits (through M&A or IPO) can be an indication of its success in developing a new product. However, there is practically no correlation between the amount of capital a company raises and its ultimate exit value. Since 2010, the R-squared between exit value and total invested capital — a measure of how correlated the two variables are — for all healthcare exits is a paltry 0.34. When you drill down to a correlation between the exit value and the amount of capital raised in a company’s Series A financing, it drops to a practically negligible value of 0.05, according to PitchBook. These statistics support the notion that just because a company raises significant amounts of capital (especially early on), there is no guarantee of a successful investment outcome. Founders shouldn’t let peer pressure or investor check size mandates dictate their financing strategy. Instead, focus on advancing your program through the key stages of technical and clinical development.

I regret to inform you that Elon has something to do with this • ZebethMedia

Hello and welcome back to Equity, a podcast about the business of startups, where we unpack the numbers and nuance behind the headlines. We hope that you are in good form this Friday, alive, well, and ready to rock. We certainly were. And in a change of pace, as our dear Mary Ann was off this week, the excellent Anita Ramaswamy joined Natasha Mascarenhas and Alex Wilhelm on the mics. (Theresa, as per usual, held down the production front!) What did we merry three get into? The following: We are back Monday for a spooky episode! Equity drops at 7 a.m. PT every Monday and Wednesday, and at 6 a.m. PT on Fridays, so subscribe to us on Apple Podcasts, Overcast, Spotify and all the casts. ZebethMedia also has a great show on crypto, a show that interviews founders, one that details how our stories come together, and more!

Crypto bear markets are a ‘great time’ to launch startups, industry execs say • ZebethMedia

There are other things to look at beyond crypto prices, the COO of Uniswap, Mary-Catherine Lader, said at ZebethMedia Disrupt last week. “Right?” She asked rhetorically. “Especially if you’re building something and you’re excited about the technology and its potential and not [viewing] crypto necessarily as an asset class.” Even though the crypto market cap is below $1 trillion, down about 55% from $2.2 trillion at the beginning of the year, ideas, startups, and big players are still entering the space. “I think many of the products in the next phase could get to a point where consumers are using a product without knowing that there’s crypto behind the scenes.” Cuy Sheffield, head of crypto at Visa “If you look at crypto market prices and pull out all of the general market decline […] what are you left with?” Brett Harrison, former president of FTX, asked during the panel. “I think you’re left with how much institutions are trading crypto and actual applications that are being built on crypto.” Compared to the 2018 crypto bear market, things have changed, Cuy Sheffield, head of crypto at Visa, said during the panel. “At the time there were questions of would anything exist outside of Bitcoin?” Today, there’s so much more for people to look at and build upon, including stablecoins, crypto infrastructure, or building a bridge between traditional finance and decentralized finance, Sheffield said.

Twitter will be delisted from the New York Stock Exchange on November 8 • ZebethMedia

Twitter’s stock will be delisted from the New York Stock Exchange and become a private company on November 8, according to a new filing with the U.S. Securities and Exchange Commission. This comes a day after Elon Musk completed the company’s takeover after a lengthy ordeal. “The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 08, 2022, pursuant to the provisions of Rule 12d2-2 (a),” the filing reads. It also indicated that the merger between Twitter and Musk’s subsidiary X Holdings II, Inc was complete. “The merger between Twitter, Inc. and X Holdings II, Inc., a wholly owned subsidiary of X Holdings I, Inc., wholly owned by Elon R. Musk became effective on October 27, 2022. Each share of Twitter, Inc. Common Stock was exchanged for USD 54.20 in cash, without interest and less any applicable withholding taxes. The Exchange also notifies the Securities and Exchange Commission that as a result of the above-indicated conditions this security was suspended from trading before market open on October 28, 2022.” At the time of writing, Twitter’s stock was trading at $53.70 — slightly lower than Musk’s buying price of $54.20. The story is developing…

54gene valuation slashed by over $100M amid job cuts and CEO exit • ZebethMedia

It’s been a strange couple of months at African genomics startup 54gene. In August, it sacked 95 employees, mostly contract staff (in labs and sales departments) hired to work in 54gene’s COVID business line launched in 2020. In September, co-founder and VP of Engineering Ogochukwu Francis Osifo left the company. And this week, founder and now ex-CEO Dr. Abasi Ene-Obong stepped down from his executive role to be replaced by General Counsel Teresia L. Bost.  This news coincided with more job cuts. The company confirmed to ZebethMedia that this second round of layoffs, which took place on Tuesday, affected over 100 staff: 55% of the total workforce remaining after the first round of layoffs. The biotech didn’t specify what roles and departments got trimmed. The Washington- and Lagos-based genomics startup has been considered the showpiece of Africa’s fledging biotech space since it got into Y Combinator in 2019. But while 54gene launched to address the gap in the global genomics market, where Africans make up less than 3% of genetic material used in pharmaceutical research, its growth in 2020 overlapped elsewhere, with the COVID-19 pandemic, and it hired aggressively to meet the demands of being one of Nigeria’s largest providers of COVID testing. Its preparedness to meet this opportunity with its clinical diagnostic arm was also a catalyst to increasing its revenue and raising two huge growth rounds in quick succession: a $15 million Series A that year and a $25 million Series B in 2021 from investors such as New York-based Adjuvant Capital, Pan-African firm Cathay AfricInvest Innovation Fund (CAIF), KdT Ventures and Endeavor Catalyst. Yet, 2022 will be a year to forget for the biotech startup. Not only has its revenues dwindled and laid off almost 200 employees, but the company’s value has also been significantly trimmed in a period when startups’ valuations are taking a beating. According to people with knowledge of the matter, 54gene’s valuation has dropped by two-thirds, from the $170 million secured when it raised its Series B to about $50 million in a bridge round involving lead investors from the company’s board. Sources also said the down round closed at a 3x to 4x liquidation preference, meaning that investors — typically the lead investor — would be paid back triple or quadruple their money before other stakeholders, including other investors, founders and employees in the case of an exit. These terms, which shift power back to investors, were rare during the venture capital boom between mid-2020 and last year but are now commonplace in this fundraising environment. 54gene didn’t confirm or deny the premise of this deal. Still, it stated in an email response: “The existing investors injected fresh capital into the company at terms that reflect current market conditions. We hope this round not only supports the company through this challenging period but also positions it for success in the future — whether it be to raise additional capital, attract strategic partners, or another future path.” Often, liquidation preferences signal that investors want to protect themselves if a growth-stage portfolio company exits at a value lower than initially expected. In some cases, the investors believe that the startup might struggle to produce a solid exit due to underlying challenges affecting its business. When the company’s first layoff news broke, allegations of financial impropriety were leveled against the then-CEO and his executives from a group of employees. And though they remain unfounded, these accusations have come to light again following Ene-Obong’s resignation. Affected employees — who claim they haven’t received their severance packages and spoke to ZebethMedia on the condition of anonymity — unsubstantially blame 54gene’s current troubles on irresponsible hiring, questionable expansion drives and misappropriation of funds. The YC-backed biotech didn’t respond to ZebethMedia’s request for comments about its former executives’ alleged mismanagement of funds and employees’ unpaid severance packages. 54gene’s tight-lippedness on the matter and Bost’s appointment from her legal role to interim CEO arbitrarily raises questions and leaves room for interpretation tilting toward these accusations, especially as both co-founders resigned a few weeks apart. However, in an email to ZebethMedia, the company subtly counterargues that Osifo’s resignation had been in process for some time and was unrelated to this month’s activities, while Bost, hired last September, was what 54gene needed — with support from COO Delali Attipoe — for its next phase. “Teresia is a well-rounded executive with a depth of experience in the global pharmaceutical and biotech industry, leading global teams and overseeing corporate governance,” the company said. “These skills, coupled with her breadth of experience driving business operations and translating complex regulatory requirements, will be invaluable at the helm of 54gene in this next phase of the company. Delali and Teresia will make a great team that together will strengthen 54gene’s position as a genomics leader in the industry.” Meanwhile, 54gene stated that its ex-chief executive “will continue to support the company in its go-forward plans such as strategic partnerships and fundraising” without explaining why he stepped down. However, according to several people with knowledge of happenings at the company, the terms of 54gene’s new deal contributed to Ene-Obong’s resignation. They say Ene-Obong — retaining his position on 54gene’s board while moving to a new senior advisor role — may have resigned as CEO in protest of 54gene’s new valuation and the liquidation preference offered by investors in the bridge round. There is some speculation that some of the investors also attempted to reprise the company’s previous prized round to get more shares while diluting that of the founders and other investors. 54gene declined to comment on the matter. The fact that 54gene had to arrange a bridge round in-house despite securing over $45 million over the last three years is a reminder that biotech projects are highly capital-intensive — for instance, it costs about $700 to sequence a human genome (one of 54gene’s main procedures). Typically, biotechs deploy investors’ funds into research while thinking about revenue later and the case isn’t different with 54gene. Still, the

business and solar energy